Continuing story · 1 report

FDA approval and access to daraxonrasib

First aired Latest aired

Gone quiet since

Where it stands

The FDA approved daraxonrasib (Rasonque), a once-daily pill for pancreatic cancer, after a trial found median survival was 13.2 months, compared with 6.7 months. Its nearly $40,000 monthly list price leaves many Medicare patients without access to the copay card; the reports give no further access or pricing developments.

Explore with HeyDex

Story trackerDay 1

1 report9 outlets11 sources1 video

  • No dated events yet
    1. Update 1FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer

    The story so far

    1. Update 1

      FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer

      Daraxonrasib targets the mutation behind more than 90% of cases and nearly doubled life expectancy in its pivotal trial, a landmark for a cancer with 13% five-year survival.

      Still open after this report

      • No verified price, coverage terms, or out-of-pocket burden in these excerpts.
      • No verified exact survival months, side-effect rates, or full label details in these excerpts.

    History

    1. Opened1 report

    Who's involved

    Places

    • Dana-Farber Cancer Institute450 Brookline Ave, Boston, MA 02215, USA1 report
    • United StatesUnited States1 report

    Every outlet we read on this story

    11 sources9 outlets1 video